Performance / Research index
CJC-1295 No-DAC
This family groups presentations labelled without DAC. The familiar studies of long-acting CJC-1295 investigated an albumin-binding compound. Their findings do not verify the contents of these vials or automatically describe a form without DAC.
Names used in the literature: CJC-1295 sin DAC · CJC-1295 no DAC · CJC-1295 without DAC
Read the evidence and its sources ↓That presentation is not part of this listing. Review the available options before adding a selection.
CJC-1295 No-DAC 5 mg
- Presentation
- 5 mg
- Catalog reference
- PMX-CJC-NODAC-5
Availability and documentation await confirmation. Listed quantities identify catalog presentations, not instructions for use.
The complete name matters
The FDA’s 2024 technical briefing distinguishes CJC-1295 and CJC-1295 DAC as different active moieties, while also separating their salt forms. This explains why a reference that simply says CJC-1295 may be insufficient. Chemical identity and the presence of DAC must be established before results can be compared meaningfully.
Sources: [1]
What the long-acting trials measured
The trials by Teichman and colleagues assessed pharmacokinetics and changes in GH and IGF-I in healthy adults. The investigated compound showed prolonged activity. These measurements describe exposure and hormonal response within that experiment; they do not demonstrate sports recovery, rejuvenation or clinical benefits of a form without DAC.
Sources: [2]
Pulsatility is not a clinical outcome
Another study examined whether pulsatile GH secretion continued during stimulation with albumin-binding CJC-1295. Its question concerned physiology: how the hormonal pattern changes. An answer about pulses does not demonstrate improvements in strength, body composition or quality of life, and does not establish equivalence between molecules with and without DAC.
Sources: [3]
Questions about this reference
Does the published duration of CJC-1295 apply without DAC?
It should not be transferred. The duration reported in the cited trials concerns the long-acting analogue. This page does not assign that pharmacokinetic profile to a presentation labelled without DAC.
Do these studies establish a combination with ipamorelin?
The cited studies do not evaluate the catalog combination. Putting two names together or linking their profiles provides no evidence about the mixture, its equivalence or its clinical outcome.
Sources and original reading
- FDA briefing: CJC-1295-related bulk drug substances, December 2024
- Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295 in healthy adults
- Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295
Content updated: . How this content is prepared and checked.
Understand before comparing